No, Ofev (nintedanib) tablets should not be crushed
The FDA-approved prescribing information explicitly states that OFEV capsules should not be opened or crushed 1. The capsules must be swallowed whole with liquid and taken with food. This is a clear directive from the drug label that takes precedence over other considerations.
Key Administration Requirements
- Swallow whole: OFEV capsules must be taken intact with liquid
- Do not crush, chew, or open: The manufacturer explicitly prohibits these manipulations
- Take with food: Required for proper absorption
- Unknown pharmacokinetics: The effect of crushing on nintedanib absorption and bioavailability has not been studied 1
Safety Concerns with Crushing
If contact with capsule contents occurs, immediate and thorough handwashing is required 1. This warning suggests potential hazards from direct exposure to the drug substance, which would be significantly increased if capsules were intentionally crushed.
The bitter taste of the contents is another reason crushing is contraindicated - the capsule design protects against this 1.
Clinical Context
While the evidence provided discusses crushing of other medications (anticoagulants like apixaban and rivaroxaban can be crushed for enteral feeding 2), and general research on tablet crushing exists 3, 4, none of this applies to nintedanib. The drug label is unambiguous.
Important Distinction
The guidelines mentioning nintedanib for interstitial lung disease 5, 6, 7 discuss its therapeutic use but provide no guidance suggesting crushing is acceptable. The monitoring recommendations focus on hepatotoxicity, diarrhea, and weight loss - not alternative administration methods 5.
Alternative Approaches
If a patient cannot swallow the capsules:
- Discuss with the prescriber whether nintedanib is appropriate for this patient
- Consider whether the 100 mg capsule strength might be easier to swallow than the 150 mg
- No liquid formulation or alternative oral dosage form is available
- The drug must be discontinued if the patient cannot tolerate capsule administration
The crushing of extended-release or specialized formulations can lead to serious adverse events, including fatalities 8, reinforcing why manufacturer instructions must be followed strictly.